HOME >> BIOLOGY >> NEWS
Paclitaxel combined with bevacizumab prolongs progression free survival in metastatic breast cancer

Results from a large, randomised clinical trial for patients with breast cancer show that those who received bevacizumab (Avastin) in combination with paclitaxel (Taxol) survived without the disease getting worse for almost twice as long as patients who received paclitaxel alone. The results were announced today at the 5th European Breast Cancer Conference (EBCC-5).

A total of 722 patients with locally recurrent or metastatic breast cancer were enrolled in the study. Patients were randomised into two treatment groups. One group received the standard treatment, paclitaxel alone and the second group received the new drug combination of paclitaxel with bevacizumab. Researchers found that patients who received bevacizumab in combination with paclitaxel had significantly improved progression free survival of 11.4 months, compared to 6.11 months with paclitaxel alone - a statistically significant difference. Initial overall survival data is also promising and shows a trend towards improved overall survival (28.4 vs 25.2 months) with the new drug combination.

"These results are good news for people with breast cancer," said the study author Dr. R. Zon, Michiana Hematology Oncology, P.C. USA, adding, "A drug with a novel mode of action on the blood vessels within the cancer has not added side effects for patients and those who received the test drugs kept their cancer under control for almost twice as long as patients who received the standard regimen. The next step will be introducing the new drug in patients whose breast cancer has not progressed to metastasis."

The clinical trial was sponsored by the National Cancer Institute (NCI) and conducted by a network of researchers led by the Eastern Cooperative Oncology Group (ECOG), one of the largest clinical cancer research organisations in the U.S. The promising trial results showed only a minimal increase in toxicity when bevacizumab was added to paclitaxel. Manageable side effects of the drug comb
'"/>

Contact: EBCC-5 Press Office
stephanie.makin@toniclc.com
33-49-392-8402
Federation of European Cancer Societies
22-Mar-2006


Page: 1 2

Related biology news :

1. Radiation therapy combined with microsurgery shows promise for curing injured spinal cord
2. Jefferson researchers develop combined procedure for uterine preservation in treating fibroids
3. High HPV concentrations combined with smoking significantly raise risks of cervical cancer
4. Study provides first-ever look at combined causes of North Atlantic and Arctic Ocean freshening
5. Vaccine combined with short-term postexposure antibiotics protects monkeys from inhalational anthrax
6. Cholesterol-lowering foods most effective when combined, U of T study
7. Biologists see combined structure of cold virus and receptor molecule
8. Saturated fats combined with genetic trait implicated in development of type 2 diabetes
9. Timing is everything for optimum combined cancer therapy
10. Encouraging results of gene therapy for severe combined immunodeficiency
11. Resveratrol prolongs lifespan and delays onset of aging-related traits in a short-lived vertebrate

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/18/2020)... ... 2020 , ... A study has been published in the ... noise control device to attenuate typical noises in a simulated neonatal intensive care ... sounds from patient monitors, ventilators and other bedside devices that would affect the ...
(Date:7/10/2020)... ... July 09, 2020 , ... Today CJ BIO announced the ... share insight on the “fifth taste” phenomenon that is revolutionizing ingredient mixes, nutritional content ... will be live on Monday, July 13, 2020 at11:00 AM (CDT) during SHIFT20, the ...
(Date:7/2/2020)... ... July 02, 2020 , ... ... B.V. (MBS) has announced a publication detailing the use of its revolutionary ... polymerase chain reaction (RT-PCR) in 16 minutes. The article, titled "Ultra-fast one-step ...
Breaking Biology News(10 mins):
(Date:7/10/2020)... (PRWEB) , ... July 09, ... ... biotechnology company, announced today that Massachusetts Institute of Technology (MIT) has expanded ... broader license allows PathSensors to move into the point-of-care diagnostic market, focusing ...
(Date:7/1/2020)... N.C. (PRWEB) , ... June 29, 2020 , ... ... reported year to date growth of 40% in 2020, despite many obstacles created ... technology, MedShift aims to increase revenue for its partnered medical practices and medical ...
(Date:6/28/2020)... ... June 25, 2020 , ... Lumeda Inc. ... today announced the company has entered a license agreement with Roswell Park Comprehensive ... globally exclusive rights to Roswell Park intellectual property surrounding a novel medical device ...
(Date:6/23/2020)... ... June 22, 2020 , ... Dracen Pharmaceuticals Inc., ... presented June 22-24 during the American Association for Cancer Research Virtual meeting. One ... the potent, consistent single agent activity in KEAP1 mutant tumor models of NSCLC. ...
Breaking Biology Technology:
Cached News: